Walleye Capital’s Meridian Bioscience Inc VIVO Stock Holding History

Walleye Capital’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-34,500	Closed	-$337K	–	1891
2019 Q4	$337K	Buy	+34,500	New	+$324K	0.02%	866

Other funds holding VIVO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SFM

Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Walleye Capital's VIVO Position: Q1 2020 in Review

Walleye Capital sold out of Meridian Bioscience Inc (VIVO) in Q1 2020, closing a stake of 34,500 shares — an estimated $337K sold.

Walleye Capital first reported a position in VIVO in Q4 2019 and held it in 1 quarter. The position peaked at $337K in Q4 2019. 168 funds tracked by Wall St. Rank hold VIVO as of Q1 2020.

Walleye Capital reported no remaining Meridian Bioscience Inc position as of Q1 2020 after selling out during the quarter.
Walleye Capital sold 34,500 Meridian Bioscience Inc shares in Q1 2020, an estimated $337K.
Walleye Capital first reported a position in Meridian Bioscience Inc in Q4 2019 and held it in 1 quarter.
Walleye Capital's Meridian Bioscience Inc position peaked at $337K in Q4 2019.
168 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2020.

Based on Walleye Capital's 13F filing for Q1 2020, filed 15 May 2020.